Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center.
Fiche du document
25 janvier 2021
- doi: 10.1038/s41541-020-00277-1
- issn: 2059-0105
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41541-020-00277-1
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33495459
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2059-0105
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_F506D1AD4F8D1
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
B lymphocytes Bursa equivalent cells Bone marrow derived cellsCiter ce document
L. Eslamizar et al., « Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center. », Serveur académique Lausannois, ID : 10.1038/s41541-020-00277-1
Métriques
Partage / Export
Résumé
The RV144 HIV-1 vaccine trial has been the only clinical trial to date that has shown any degree of efficacy and associated with the presence of vaccine-elicited HIV-1 envelope-specific binding antibody and CD4+ T-cell responses. This trial also showed that a vector-prime protein boost combined vaccine strategy was better than when used alone. Here we have studied three different priming vectors-plasmid DNA, recombinant MVA, and recombinant VSV, all encoding clade C transmitted/founder Env 1086 C gp140, for priming three groups of six non-human primates each, followed by a protein boost with adjuvanted 1086 C gp120 protein. Our data showed that MVA-priming favors the development of higher antibody binding titers and neutralizing activity compared with other vectors. Analyses of the draining lymph nodes revealed that MVA-prime induced increased germinal center reactivity characterized by higher frequencies of germinal center (PNA hi ) B cells, higher frequencies of antigen-specific B-cell responses as well as an increased frequency of the highly differentiated (ICOS hi CD150 lo ) Tfh-cell subset.